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Abstract
Protective autoimmunity (PA) is a physiological response to central nervous system trauma that has demonstrated to
promote neuroprotection after spinal cord injury (SCI). To reach its beneficial effect, PA should be boosted by immunizing
with neural constituents or neural-derived peptides such as A91. Immunizing with A91 has shown to promote
neuroprotection after SCI and its use has proven to be feasible in a clinical setting. The broad applications of neural-
derived peptides make it important to determine the main features of this anti-A91 response. For this purpose, adult
Sprague-Dawley rats were subjected to a spinal cord contusion (SCC; moderate or severe) or a spinal cord transection
(SCT; complete or incomplete). Immediately after injury, animals were immunized with PBS or A91. Motor recovery, T cell-
specific response against A91 and the levels of IL-4, IFN-c and brain-derived neurotrophic factor (BDNF) released by A91-
specific T (TA91) cells were evaluated. Rats with moderate SCC, presented a better motor recovery after A91 immunization.
Animals with moderate SCC or incomplete SCT showed significant T cell proliferation against A91 that was characterized
chiefly by the predominant production of IL-4 and the release of BDNF. In contrast, immunization with A91 did not
promote a better motor recovery in animals with severe SCC or complete SCT. In fact, T cell proliferation against A91 was
diminished in these animals. The present results suggest that the effective development of PA and, consequently, the
beneficial effects of immunizing with A91 significantly depend on the severity of SCI. This could mainly be attributed to
the lack of TA91 cells which predominantly showed to have a Th2 phenotype capable of producing BDNF, further
promoting neuroprotection.
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Introduction
Protective autoimmunity (PA) is a physiological T cell-
dependent response to neural antigens that protects rather than
destroys neural tissue [1–5]. In order to obtain the maximal
benefits of PA, it is possible to boost this response by immunizing
with neural constituents. However, when immunizing with self-
antigens there is always a risk of developing a pathological
autoimmune response. At the moment, PA can be boosted with
non-encephalitogenic peptides such as A91, these have significant
evidence of their neuroprotective effects after SCI. A91 is a
peptide derived from myelin basic protein (sequence 87–99) but
replacing the lysine residue at position 91 with alanine.
Immunizing with A91 reduces tissue damage and improves motor
recovery after moderate SCI. The therapeutic effect of this
strategy has been improved by combining A91 immunization with
other therapies [6]. As immunizing with these types of peptides
promises important expectations in the future, it is relevant to
better understand the general conditions needed to achieve its
beneficial effects.
The effect of PA depends on the rapid and proper
development of the specific immune response [7] in such a
way that any disturbance could derail the benefits of PA. A
previous study in our laboratory showed that the adaptive
immune response to any immunogen depends on the severity of
SCI [8]; the more severe the injury (severe SCC) the more
impaired the immune response. Since the beneficial outcome of
PA depends on the proper development of this response we
attempted to evaluate motor recovery, lymphocyte proliferation,
T cell phenotype and neurotrophin production in animals
subjected to SCI. Injury consisted of either a moderate SCC,
severe SCC, incomplete SCT or complete SCT. A91 induced a
better motor recovery in rats with moderate SCC. This
beneficial effect was associated with a proliferative T cell
response to A91 and the subsequent improvement in motor
recovery. The proliferative response was characterized by a Th2
phenotype and the significant release of BDNF. In contrast,
severe injuries eliminated the beneficial effect of A91 on motor
recovery. This failure was associated to the decrease of the
specific immune response towards A91.
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Animals
Adult female Sprague-Dawley rats (13–14 weeks old, 200–
220 g) were supplied by the Animal Breeding Center of Proyecto
Camina A. C. Efforts were made to minimize the number of
animals used and their suffering.
Ethics Statement
All procedures were in accordance with the National Institutes
of Health (US) Guide for the Care and Use of Laboratory Animals
and the Mexican Official Norm on Principles of Laboratory
Animal Care (NOM 062-ZOO-1999). All animal procedures were
approved by the National Council of Science and Technology of
Mexico (CONACYT) Animal Bioethics and Welfare Committee
(ID: 57204; CSNBTBIBAJ 090812 960).
Spinal Cord Injury
Rats were anesthetized by intramuscular injection of ketamine
(80 mg/kg; PISA Laboratories, Mexico City, Mexico) and
xylazine (12.5 mg/kg; Bayer Laboratories, Mexico City, Mexico).
One hour after anesthesia induction the spinal cord was exposed
and the animals were subjected to a SCC or SCT at T9. For
contusion, a 10-g rod was dropped onto the exposed spinal cord
from a height of 25 (moderate) or 50 mm (severe), using the NYU
impactor (NYU, New York). This device is shown to inflict a well-
calibrated contusive injury of the spinal cord [9]. Prior to
transection, the dura mater was dissected and separated from
the spinal cord with a 30-gauge needle. Complete transection was
performed by sliding a straight-edged scalpel blade through the
spinal cord. Accuracy of the injury was visually verified by passing
a micro-hook through the internal contour of the dura. For
incomplete transection, approximately 50% of the dorsal spinal
cord (including the corticospinal tracts) was transversely cut with
iridectomy scissors. After injury, the aponeurotic plane and the
skin were sutured separately with nylon thread.
Animal Care
The animals were matched for age and weight in each
experiment and housed in pairs in a light- and temperature-
controlled room. To minimize stress, animals were handled daily
at least once a day 7 days prior to the surgical procedure.
Sterile bedding and filtered water was replaced daily. Bladder
expression was assisted manually twice a day until automatic
voidance was regained. During the first week after contusion the
animals received a course of enrofloxacine (Marvel, Mexico City,
Mexico) in their drinking water at an approximate dose of 64 mg/
kg/d. All rats were carefully monitored for evidence of postsurgical
complications. Animals with signs of infections were excluded from
the study.
Antigen
The A91 peptide was derived from the encephalitogenic
sequence of myelin basic protein (MBP; amino acids 87–99).
Nonencephalitogenicity was obtained by replacing the lysine
residue at position 91 with alanine. The modified peptide was
purchased from Invitrogen Life Technologies (San Diego, CA,
USA). Reverse-phase HPLC confirmed that the purity of the A91
peptide was .95%.
Active immunization
Rats were immunized subcutaneously at the base of the tail with
150 mg of A91 or phosphate buffered saline (PBS) emulsified in an
equal volume of complete Freund’s adjuvant (CFA) containing
0.5 mg/ml Mycobacterium tuberculosis (Sigma, St. Louis MO) within
a 60 min time frame after injury.
Assessment of functional recovery
Motor functional recovery was assessed using the Basso, Beattie
& Bresnahan (BBB) open-field test of locomotor ability [10]. The
recovery was scored on the BBB Locomotor Rating Scale of 0
(complete paralysis) to 21 (complete mobility). Animals were tested
weekly during an 8-week period by observers blinded to the
treatment received by each rat.
T cell proliferation
Cells were pooled from excised inguinal lymph nodes 14 days
after SCI (n=4). The cells were cultured in quintuplicate flat-
bottomed wells in 0.2 ml of RPMI-1640 medium (GIBCO, New
York) supplemented with 10% fetal bovine serum (Gibco, New
York) on a 96-well microtiter plate. Cells (2.5610
5 cells per well)
were cultured 72 hrs in antigen-free medium or together with A91
(10 mg/ml), ovalbumin (OVA; 10 mg/ml; Sigma), or concanava-
lin-A (ConA; 10 mg/ml; Sigma St. Louis MO) at 37uCi n5 %C O 2.
After two washes with RPMI-1640, cells were labeled with
carboxifluorescein diester amine (CFSE) (Molecular Probes),
CFSE-labeled cells divide and its progeny are endowed with half
the number of carboxyfluorescein-tagged molecules and thus each
cell division can be assessed by measuring the corresponding
decrease in cell fluorescence. CFSE was used at a final
concentration of 1 mM and, 5 ml/well of this solution were rapidly
dispensed into the cell suspension insuring a homogeneous
labeling. Cells were then incubated for 24 h at 37uC. Staining
was halted by the addition of an equal volume of fetal bovine
serum. The proliferative response was determined by flow
cytometry. Cells were also stained with phycoerythrin-labeled
anti-CD4 monoclonal antibodies (BD Pharmigen, San Diego,
CA), unstained cells were used as controls. Cells stained with
CFSE and CD4 were analyzed. For analysis, the area of
lymphocytes was selected based on the light scattering character-
istics (size/granularity) of these cells. Afterwards, the area of CD4+
cells was selected and analyzed for CFSE fluorescence. Mean
fluorescence intensity data was obtained from fluorescence
histograms to evaluate the fractions of T cells that have completed
certain number of divisions. Ten thousand events were collected
for each sample on a FACSCalibur flow cytometer (BD Bioscence,
Mountain View, CA) and analyzed using CellQuest Pro software
(BD Bioscences). The stimulation index (SI) was calculated by
dividing the mean percentage of proliferation in experimental
wells by the mean percentage of proliferation in the corresponding
control wells (cells cultured without antigen).
Table 1. Number of animals per group used to evaluate
motor recovery.
Groups
Number of animals
Immunized with
A91 PBS
Moderate SCC 10 10
Severe SCC 10 10
Complete SCT 10 10
SCC: Spinal cord contusion; SCT: Spinal cord transection.
doi:10.1371/journal.pone.0032027.t001
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An ELISA kit (BD Biosciences, San Diego CA) was used to
analyze the concentration of either IL-4 or IFN-c in supernatants
obtained from T cell proliferation assays as described by the
manufacturer.
BDNF analysis
An ELISA kit (Chemicon International) was used to analyze the
concentration of BDNF in supernatants obtained from T cell
proliferation assays as described by the manufacturer.
Statistical analysis
Data was analyzed using the GraphPad Prism 3.0 software and
presented as mean 6 standard deviation (SD). Motor recovery was
analyzed by two-factor ANOVA for repeated measures. The
proliferative response was evaluated using the Kruskal-Wallis test
with post-hoc Mann-Whitney U tests. In the analysis of the IL-4/
IFN-c index and BDNF levels a Student’s t-test was performed.
Differences of p#0.05 were considered statistically significant.
Results
A91-induced motor recovery is impaired by severe SCI
The first step of this work, investigated the effect of
immunizing with A91 on the functional motor recovery of
animals subjected to either a moderate SCC, severe SCC, or a
complete SCT (n=10 per group). In all cases, the effect of A91
immunization was compared to PBS immunization controls
(n=10, see Table 1). Figure 1A depicts that one week after injury,
A91 immunization promoted a better recovery in moderate SCC
animals (7.960.6 vs. 4.260.9, A91 and PBS immunization
respectively; mean 6 SD). Towards the end of study (week 8),
A91-treated rats showed a significant improvement in recovery
compared to PBS-immunized animals (10.260.5 vs. 8.360.3,
A91 and PBS immunization respectively; p,0.05, F=11.67). In
contrast, A91 immunization did not promote any functional
improvement in animals subjected to severe SCC (Figure 1B). At
the end of the evaluation period, the recovery of A91-immunized
rats (5.0960.1) did not differ significantly from PBS-immunized
controls (5.060.2, p.0.05, F=0.93). Finally, animals subjected
to complete SCT had poor post-injury recovery (Fig. 1C). As
Figure 1. Motor recovery of spinal cord injured rats. Animals
were subjected to a moderate (A) or severe spinal cord contusion (B).
The recovery of rats subjected to a complete SCT is also shown (C). In all
cases, animals were treated either with A91 or PBS. Severe injuries
abolished the beneficial effect induced by immunizing with A91.
*
Different from PBS group (p,0.05, two-way ANOVA for repeated
measures). Each point represents the mean 6 SD of 10 rats.
doi:10.1371/journal.pone.0032027.g001
Table 2. Number of animals per group used to evaluate the
proliferative response.
Groups
Number of animals
Immunized with
A91 PBS
Moderate SCC 5 5
Severe SCC 5 5
Complete SCT 5 5
Incomplete SCT 5 5
SCC: Spinal cord contusion; SCT: Spinal cord transection.
doi:10.1371/journal.pone.0032027.t002
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rable motor recovery that was very low, even towards the end of
the study (1.660.2 vs. 1.160.1, A91 and PBS respectively;
p.0.05,F=0.02).
Severe SCI impairs the ability to develop an adaptive TA91
cell response after immunization
In view of the above results, we now intended to find if
immunization with A91 was inducing a specific immune
response in animals with severe SCC or complete SCT. The
rationale for this study was based on the idea that the absence
of neuroprotection could be the result of a failure to induce an
anti-A91 response (PA). For this purpose, twenty rats were
subjected to a moderate (n=10), or severe (n=10) SCC;
another 20 were subjected to a complete (n=10) or incomplete
SCT (n=10, see Table 2). The last group was added to
investigate the proliferative response in animals that received
an incomplete transection of the spinal cord. Immediately after
injury, animals were immunized with A91 (n=5)orPBS(n=5,
see Table 2). Total leukocyte cell fractions obtained from
lymph nodes of these animals were assayed. Figures 2 and 3
show that A91 immunization induced significant proliferation
of TA91 cells in rats with moderate SCC (Fig. 2A; SI=
2.560.42, mean 6 SD) or incomplete SCT (Fig. 2C; SI=
2.660.2). However, in the case of rats subjected to severe SCC
(Fig. 2B; SI=0.9060.13) or complete SCT (Fig. 2D; SI=0.86
0.05), the proliferative response against A91 was absent (see
also figure 3).
TA91 cells have a prevalent Th2 phenotype and secrete
increased amounts of BDNF
In order to better characterize the proliferative response
induced by A91 immunization in moderately injured animals
(rats presenting the neuroprotective effect), we now explored the
IL-4/IFN-c index in the supernatants obtained from the
proliferation assays stimulated with A91 peptide and performed
to PBS- and A91-immunized animals (previous experiment).
Immunizing with A91 caused an increased release of IL-4 in
proliferating lymphocytes. In both moderate SCC (Fig. 4A;
2.9460.3, mean 6 SD; p,0.0001 vs. PBS, Student’s t-test) and
incomplete SCT rats (Fig.4B; 3.1660.6; p=0.001 vs. PBS,
Student’s t-test) the IL-4/IFN-c index of A91-immunized rats
was significantly higher than that observed for PBS-immunized
controls (1.260.2 and 1.0160.5 respectively).
Previous studies have demonstrated that Cop-1- (another
neural-derived peptide) specific T cells are capable of producing
high levels of BDNF [11]. The next step of this study explored the
concentration of BDNF in the supernatant of cells from A91- or
PBS-immunized rats that were co-cultured with A91. As is shown,
the proliferative response induced by A91 in moderate SCC rats
was capable of producing increased amounts of BDNF (Fig. 5A
and B). The levels of this neurotrophin were significantly higher in
cultures from A91-stimulated animals than those observed in PBS-
stimulated controls.
Figure 2. Effect of spinal cord injury on the proliferative
response to A91. T cell proliferation against A91 was analyzed in rats
with moderate (A) or severe (B) spinal cord contusion (SCC). The same
evaluation was performed on rats with incomplete (C) or complete (D)
spinal cord transection (SCT). Severe SCC and complete SCT inhibited
the proliferative response against A91.
* Different from PBS group
(p=0.01, Mann-Whitney U test). Bars represent the mean 6 SD of 5 rats.
doi:10.1371/journal.pone.0032027.g002
Injury Severity Affects Protective Autoimmunity
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For some time, the immune response has been considered as a
harmful mediator after SCI [12]. Nevertheless, there is strong
evidence supporting that immune cells improve the neurological
outcome after injury [6,13]. For instance, the immune response
developed after immunization with neural-derived peptides (PA) is
capable of ameliorating neurotoxicity [14,15], lipid peroxidation
[16] and other degenerative mechanisms [7,17,18]. It is clear that
immune cells promote a microenvironment where different
destructive phenomena are being suppressed, providing tissue
protection and improving the functional recovery [2].
Previous studies have shown that immunizing with A91
activates a specific immune response that provides significant
neuroprotection and motor recovery after a moderate SCC [6]. In
order to better understand this anti-A91 response we investigated
the features of PA under different SCI severities. The results
indicated that the improvement in motor function observed after
moderate SCI was associated with the prevalence of an anti-
inflammatory Th2 phenotype. In addition, this Th2 phenotype
was capable of releasing significant amounts of BDNF. Previous
studies have shown that immunizing with A91 induces a Th2
phenotype in models of experimental autoimmune encephalomy-
elitis (EAE), in this case the immunization ameliorated the course
of EAE [19]. The present work demonstrated, for the first time,
that A91 also induces a Th2 phenotype in experimental models of
SCI. That finding provides substantial elements to explain, at least
in part, our previous observations about the inhibitory effect of
A91 immunization on iNOS gene expression and nitric oxide
production [20]. Cytokines like IL-4 and IL-10 downregulate the
expression of the iNOS gene, we hypothesized that this effect was
caused by the action of a predominantly IL-4-secreting Th2
phenotype [21,22]. On the other hand, the fact that this Th2
phenotype is capable of increasing BDNF production also provides
more elements to explain the protective action of A91 immuni-
zation. BDNF prevents the death of motor neurons in newborn
rats after nerve transection through its action on tyrosine kinase
(Trk) receptors [23] and also rescues spinal cord motor neurons
Figure 3. Representative histograms of A91-immunized animals. The ability of T cells to proliferate in the presence of A91 peptide was
evaluated using CFSE assays and flow cytometry. Cells stained for CFSE and CD4 were analyzed. Ten thousand events were collected for each sample.
doi:10.1371/journal.pone.0032027.g003
Figure 4. IL-4/IFN-c index in the supernatant of T cells exposed to
A91. Lymphocytes were obtained from rats with moderate spinal cord
contusion (A) or incomplete spinal cord transection (B). TA91 cells
predominantly released IL-4.
* Different from PBS (p,0.0001 (A), p=0.001
(B) Student’s t-test). Bars represent the mean 6SD of 5 rats. Data was taken
from one of three experiments where the same effect was observed.
doi:10.1371/journal.pone.0032027.g004
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of this neurotrophic factor could also be a relevant mechanism of
neuroprotection.
Another significant finding was the reduction of the A91
response after severe SCI. With regard to this, it is worth
mentioning that this loss was observed using the same immuni-
zation scheme used in moderate SCI. Previous studies in our
laboratory have shown that immunizing with 150 mg of A91 is
sufficient to obtain neuroprotection [16] and improve functional
recovery after a moderate SCI [6]. The present work applied the
same scheme and was unable to induce the specific immune
response after either a severe SCC or a complete SCT. Moreover,
the absence of an A91 response was associated with an impaired
motor recovery. The lack of a response could be the result of a
state of immunosuppression developed after injury. The existence
of a SCI-immune depression syndrome (SCI-ICD) has been
reported to develop during the first seven days after injury [25].
Furthermore, our group demonstrated that severe SCC further
worsens this state of immunodepression making humoral and
cellular responses almost inexistent [8]. The impact of SCI on the
immune system is the result of several factors. For instance,
immediately after injury there is a period of increased autonomic
discharge causing catecholamine over-production. Catechol-
amines are capable of inhibiting lymphocyte proliferation [26]
and cause rapid and extensive apoptosis in lymphoid organs [27].
After injury there is also a significant increase in corticosterone, a
steroid hormone involved in regulation of the immune response
[28,29]. According to the above observations, it appears that the
scenario induced by SCI does not allow immune cells to be
competent enough to undergo adaptive immunity activation.
However, several studies (including the present manuscript)
demonstrate that in spite of immune system-suppression after
injury, the activation of a specific response against an immunogen
is still feasible [6,16,30,31]. Nevertheless, the severity of the injury
could be a strong determinant in the functioning of the immune
system. In light of this notion, and considering the results of our
previous work, it is likely that the more severe the SCI, the larger
the impairment in immunological function [8]. Under this context,
we could explain the failure to induce an anti-A91 response and
thus the failure in functional motor recovery in animals with severe
injuries.
In view of the present results, it should be stressed that
stimulation of PA cannot be performed under the basis of a
general paradigm, even if the animals belong to the same strain or
share similar weight and age. The previous observation indicates
that experimental protocols evaluating PA in animals with severe
SCI should consider the altered activation of the adaptive immune
response.
Finally, in animals with complete SCT it is difficult to expect
that PA (even if it is developed) will exert its protective actions.
Since there are no spared axons in complete SCT this model does
not benefit from the effects of neuroprotection. Therefore the
beneficial mechanisms exerted by PA could be directed towards
ameliorating the damage by restoring the neural tissue; however
this phenomenon should be further explored.
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